Our pivotal-stage monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP), and is currently in late-stage clinical development for the prevention of migraine.
Alder BioPharmaceuticals® Presents New Data on Migraine-Free Months, Migraine Severity and Quality of Life, Demonstrating Eptinezumab’s Clinical Profile for Migraine Prevention
- Posters presented at the 2019 American Headache Society meeting highlight eptinezumab’s safety profile and suppression of... LEARN MORE
The U.S. Food and Drug Administration (FDA) accepted Alder’s Biologics License Application for eptinezumab in April 2019, with a Prescription Drug User Fee Act (PDUFA) target action date of February 21, 2020.